{ "schemaVersion": "1.0.0", "project": "Type1Cure.com", "generatedAt": "2026-10-20T01:17:02.002Z", "staleFallback": false, "itemCount": 33, "sourceCount": 4, "trustTiers": { "T0": "Official registry or regulator", "T1": "Peer-reviewed literature index", "T2": "Government or nonprofit authority", "T3": "Company or press source", "T4": "News or broad media source", "T5": "Community, creator, podcast, or anecdotal source", "T5-preprint": "Preprint, not peer reviewed" }, "medicalDisclaimer": "Type1Cure is an information and research-monitoring product, not medical advice. Verify source details with clinicians and official records before making care decisions.", "sourceHealth": [ { "sourceId": "openfda_device_recalls", "sourceName": "openFDA device recalls", "status": "ok", "itemCount": 10, "checkedAt": "2026-10-20T01:17:02.555Z", "elapsedMs": 551, "detail": "Fetched recent diabetes-adjacent device recalls." }, { "sourceId": "clinicaltrials_gov_v2", "sourceName": "ClinicalTrials.gov", "status": "ok", "itemCount": 11, "checkedAt": "2026-10-20T01:17:02.680Z", "elapsedMs": 125, "detail": "Fetched recruiting Type 1 diabetes studies." }, { "sourceId": "pubmed_ncbi_eutilities", "sourceName": "PubMed", "status": "ok", "itemCount": 12, "checkedAt": "2026-10-20T01:17:03.442Z", "elapsedMs": 762, "detail": "Fetched via NCBI E-utilities." }, { "sourceId": "crossref_works", "sourceName": "Crossref", "status": "ok", "itemCount": 0, "checkedAt": "2026-10-20T01:17:03.734Z", "elapsedMs": 291, "detail": "Fetched DOI-indexed Type 1 diabetes publications." } ], "errors": [], "items": [ { "id": "openfda-device-recall:222528", "sourceId": "openfda_device_recalls", "sourceName": "openFDA device recalls", "category": "Safety", "trustTier": "T0", "evidenceLabel": "FDA recall database", "urgency": "Act", "title": "Medtronic MiniMed, Inc.: Brand Name: MiniMed Flex Product Name: MiniMed Flex Insulin Pump Model/Catalog Numbers: MMT-8062; MMT-8072 Product Description: The MiniMed Flex pump is an alternate controller en...", "summary": "Some MiniMed Flex insulin pumps were released with missing (i.e., devices with no result or abort test results are presumed to have failed) or failed verification test results in one or more of 9 functional tests. The unverified/failed pumps released to users potentially have one or more of the following issues: inoperable pump at setup, lack of protection for moisture exposur... Action: On 08/20/2026, Technical Support called affected customers to inform that, MiniMed identified an issue in which certain MiniMed...", "whyItMatters": "Device and supply recalls can affect insulin delivery, glucose readings, replacement needs, and urgent family safety decisions.", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?id=222528", "publishedAt": "2026-10-05", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "safety", "recall", "fda", "device" ], "metadata": { "cfresId": "222528", "recallNumber": "Z-0088-2027", "status": "Open, Classified", "firm": "Medtronic MiniMed, Inc.", "initiatedAt": "2026-08-20", "postedAt": "2026-10-05" } }, { "id": "clinicaltrials:NCT04011020", "sourceId": "clinicaltrials_gov_v2", "sourceName": "ClinicalTrials.gov", "category": "Trials", "trustTier": "T0", "evidenceLabel": "Official recruiting registry", "urgency": "Act", "title": "Clinical Application of Stem Cell Educator Therapy in Type 1 Diabetes", "summary": "RECRUITING, PHASE3. Interventions: Stem Cell Educator therapy. Locations: Paramus, New Jersey, United States | Paramus, New Jersey, United States. Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease that causes a deficit of pancreatic islet beta cells. Millions of individuals worldwide have T1D, and incidence increases annually. Several recent clinical trials point to the need for an approach that produces comprehensive immune modulation at both...", "whyItMatters": "Recruiting status can change quickly. Families should review official eligibility, location, burden, and care-team fit before sharing health information.", "url": "https://clinicaltrials.gov/study/NCT04011020", "publishedAt": "2026-10-05", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "trial", "recruiting", "clinicaltrials.gov" ], "metadata": { "nctId": "NCT04011020", "status": "RECRUITING", "phase": "PHASE3", "interventions": "Stem Cell Educator therapy", "locations": "Paramus, New Jersey, United States | Paramus, New Jersey, United States" } }, { "id": "clinicaltrials:NCT07831798", "sourceId": "clinicaltrials_gov_v2", "sourceName": "ClinicalTrials.gov", "category": "Trials", "trustTier": "T0", "evidenceLabel": "Official recruiting registry", "urgency": "Act", "title": "VV-14300 for the Treatment of Type 1 Diabetes", "summary": "RECRUITING, PHASE1, PHASE2. Interventions: VV-14300. Locations: Toronto, Canada | Christchurch, New Zealand. This study is testing VV-14300 in adults with long-standing type 1 diabetes (T1D) whose blood sugar is not well controlled despite using an automated insulin delivery (AID) system. VV-14300 is an investigational gene therapy that is injected into muscle and is designed to help remove excess sugar from the blood.", "whyItMatters": "Recruiting status can change quickly. Families should review official eligibility, location, burden, and care-team fit before sharing health information.", "url": "https://clinicaltrials.gov/study/NCT07831798", "publishedAt": "2026-10-05", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "trial", "recruiting", "clinicaltrials.gov" ], "metadata": { "nctId": "NCT07831798", "status": "RECRUITING", "phase": "PHASE1, PHASE2", "interventions": "VV-14300", "locations": "Toronto, Canada | Christchurch, New Zealand" } }, { "id": "openfda-device-recall:221918", "sourceId": "openfda_device_recalls", "sourceName": "openFDA device recalls", "category": "Safety", "trustTier": "T0", "evidenceLabel": "FDA recall database", "urgency": "Act", "title": "Tandem Diabetes Care, Inc.: Brand Name: Tandem t:slim mobile application Product Name: t:slim Mobile Application, iOS Model/Catalog Number: iOS software version 2.13 Software Version: iOS software version 2....", "summary": "A beta (early-release) version of the iOS application, version 2.13 (TestFlight) had a software issue preventing successful pairing of the t:slim application with Abbott FreeStyle Libre 3 Plus (FSL3P) continuous glucose monitoring (CGM) sensors, resulting in the insulin pump being unable to establish a near-field communication (NFC) connection with the CGM and requiring FSL3P... Action: On 07/16/2026, an \"URGENT MEDICAL DEVICE CORRECTION\" communication was sent via certified mail to customers informing them that a...", "whyItMatters": "Device and supply recalls can affect insulin delivery, glucose readings, replacement needs, and urgent family safety decisions.", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?id=221918", "publishedAt": "2026-09-29", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "safety", "recall", "fda", "device" ], "metadata": { "cfresId": "221918", "recallNumber": "Z-3330-2026", "status": "Open, Classified", "firm": "Tandem Diabetes Care, Inc.", "initiatedAt": "2026-07-16", "postedAt": "2026-09-29" } }, { "id": "clinicaltrials:NCT05153070", "sourceId": "clinicaltrials_gov_v2", "sourceName": "ClinicalTrials.gov", "category": "Trials", "trustTier": "T0", "evidenceLabel": "Official recruiting registry", "urgency": "Act", "title": "Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes", "summary": "RECRUITING, PHASE2. Interventions: Cyclosporin, ILT101, Placebo. Locations: Paris, France. Type 1 diabetes (T1D) is caused by the destruction of insulin-producing cells by effector T cells (Teffs), due to a deficiency of regulatory T cells (Tregs). Ciclosporin effectively blocks the Teffs and controls diabetes, but cannot be considered as a long-term treatment. Low-dose interleukin-2 (ld IL-2) activates and expands Tregs in humans. Hence, Ld IL-2 in patie...", "whyItMatters": "Recruiting status can change quickly. Families should review official eligibility, location, burden, and care-team fit before sharing health information.", "url": "https://clinicaltrials.gov/study/NCT05153070", "publishedAt": "2026-09-09", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "trial", "recruiting", "clinicaltrials.gov" ], "metadata": { "nctId": "NCT05153070", "status": "RECRUITING", "phase": "PHASE2", "interventions": "Cyclosporin, ILT101, Placebo", "locations": "Paris, France" } }, { "id": "openfda-device-recall:221440", "sourceId": "openfda_device_recalls", "sourceName": "openFDA device recalls", "category": "Safety", "trustTier": "T0", "evidenceLabel": "FDA recall database", "urgency": "Act", "title": "Medtronic MiniMed, Inc.: MiniMed 640G Insulin Pump, Model: MMT-1711, MMT-1712;", "summary": "Loaner insulin pumps may have been cleaned with chemically incompatible products that could damage the pump case or keypad, allow moisture ingress, and result in insulin over- or under-delivery, potentially causing hypoglycemia, hyperglycemia, or diabetic ketoacidosis. Action: On 7/13/2026, field safety notices were sent to customers asking them to do the following: 1) Stop using the loaner pump and contact the firm to arrange for loaner pump return. 2) Contact your Healthcare Professional (H...", "whyItMatters": "Device and supply recalls can affect insulin delivery, glucose readings, replacement needs, and urgent family safety decisions.", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?id=221440", "publishedAt": "2026-08-18", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "safety", "recall", "fda", "device" ], "metadata": { "cfresId": "221440", "recallNumber": "Z-2980-2026", "status": "Open, Classified", "firm": "Medtronic MiniMed, Inc.", "initiatedAt": "2026-07-13", "postedAt": "2026-08-18" } }, { "id": "openfda-device-recall:221569", "sourceId": "openfda_device_recalls", "sourceName": "openFDA device recalls", "category": "Safety", "trustTier": "T0", "evidenceLabel": "FDA recall database", "urgency": "Act", "title": "Medtronic MiniMed, Inc.: MiniMed 670G Insulin Pump, Model: MMT-1781, MMT-1782;", "summary": "Loaner insulin pumps may have been cleaned with chemically incompatible products that could damage the pump case or keypad, allow moisture ingress, and result in insulin over- or under-delivery, potentially causing hypoglycemia, hyperglycemia, or diabetic ketoacidosis. Action: On 7/13/2026, field safety notices were sent to customers asking them to do the following: 1) Stop using the loaner pump and contact the firm to arrange for loaner pump return. 2) Contact your Healthcare Professional (H...", "whyItMatters": "Device and supply recalls can affect insulin delivery, glucose readings, replacement needs, and urgent family safety decisions.", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?id=221569", "publishedAt": "2026-08-18", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "safety", "recall", "fda", "device" ], "metadata": { "cfresId": "221569", "recallNumber": "Z-2981-2026", "status": "Open, Classified", "firm": "Medtronic MiniMed, Inc.", "initiatedAt": "2026-07-13", "postedAt": "2026-08-18" } }, { "id": "openfda-device-recall:221570", "sourceId": "openfda_device_recalls", "sourceName": "openFDA device recalls", "category": "Safety", "trustTier": "T0", "evidenceLabel": "FDA recall database", "urgency": "Act", "title": "Medtronic MiniMed, Inc.: MiniMed 780G Insulin Pump, Model: MMT-1885CLW, MMT-1886CLW", "summary": "Loaner insulin pumps may have been cleaned with chemically incompatible products that could damage the pump case or keypad, allow moisture ingress, and result in insulin over- or under-delivery, potentially causing hypoglycemia, hyperglycemia, or diabetic ketoacidosis. Action: On 7/13/2026, field safety notices were sent to customers asking them to do the following: 1) Stop using the loaner pump and contact the firm to arrange for loaner pump return. 2) Contact your Healthcare Professional (H...", "whyItMatters": "Device and supply recalls can affect insulin delivery, glucose readings, replacement needs, and urgent family safety decisions.", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?id=221570", "publishedAt": "2026-08-18", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "safety", "recall", "fda", "device" ], "metadata": { "cfresId": "221570", "recallNumber": "Z-2982-2026", "status": "Open, Classified", "firm": "Medtronic MiniMed, Inc.", "initiatedAt": "2026-07-13", "postedAt": "2026-08-18" } }, { "id": "openfda-device-recall:221103", "sourceId": "openfda_device_recalls", "sourceName": "openFDA device recalls", "category": "Safety", "trustTier": "T0", "evidenceLabel": "FDA recall database", "urgency": "Act", "title": "Medtronic MiniMed, Inc.: MiniMed Go App, Model: MMT-8600 (iOS), MMT-8601 (Android)", "summary": "For MiniMed Go app version 1.0.0 and 1.1.0, when the Set day and night is turned OFF and missed dose or Correct high glucose alerts are enabled, the associated alerts will not be triggered during the nighttime. This could result in missed rapid-acting insulin doses without the user s knowledge, and may lead to delayed therapy and an increased risk of hyperglycemia. Action: On 6/16/2026 In-App Push Notifications were sent to customers entitled, Important Field Safety Corrective Action required on your MiniMed Go ap...", "whyItMatters": "Device and supply recalls can affect insulin delivery, glucose readings, replacement needs, and urgent family safety decisions.", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?id=221103", "publishedAt": "2026-07-23", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "safety", "recall", "fda", "device" ], "metadata": { "cfresId": "221103", "recallNumber": "Z-2778-2026", "status": "Open, Classified", "firm": "Medtronic MiniMed, Inc.", "initiatedAt": "2026-06-16", "postedAt": "2026-07-23" } }, { "id": "openfda-device-recall:221053", "sourceId": "openfda_device_recalls", "sourceName": "openFDA device recalls", "category": "Safety", "trustTier": "T0", "evidenceLabel": "FDA recall database", "urgency": "Act", "title": "Medtronic MiniMed, Inc.: MiniMed 780G Insulin Pump, REF: MMT-1885, MMT-1886, MMT-1895, MMT-1896", "summary": "A software anomaly can occur when the pump is paired with the Instinct sensor. Under certain circumstances, the pump unexpectedly stops delivering insulin and displays two error messages back-to-back: Pump Error 53 followed immediately by Pump Error 23. Insulin delivery will stop which may lead to delayed therapy and an increased risk of hyperglycemia or diabetic ketoacidosis... Action: On 5/27/2026, field safety notices were emailed to customers who were asked to do the following: 1) Update insulin pump software...", "whyItMatters": "Device and supply recalls can affect insulin delivery, glucose readings, replacement needs, and urgent family safety decisions.", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?id=221053", "publishedAt": "2026-07-08", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "safety", "recall", "fda", "device" ], "metadata": { "cfresId": "221053", "recallNumber": "Z-2698-2026", "status": "Open, Classified", "firm": "Medtronic MiniMed, Inc.", "initiatedAt": "2026-05-27", "postedAt": "2026-07-08" } }, { "id": "openfda-device-recall:220614", "sourceId": "openfda_device_recalls", "sourceName": "openFDA device recalls", "category": "Safety", "trustTier": "T0", "evidenceLabel": "FDA recall database", "urgency": "Act", "title": "Insulet Corporation: Omnipod 5 Pods. Includes the below Model/REF Numbers: 1. POD-OMNI-I1-6720. 2. POD-OMNI-I1-6220. 3. OMNI-I1-6729 (10-Pack), OMNI-I1-6720 (Single Pod). 4. OMNI-I1-6220. 5. OMNI-I1-6...", "summary": "External soft cannula damage during manufacturing that results in insulin leaking around the Pod instead of being delivered to the user regardless of basal or bolus delivery. The primary failure mode is pump under-delivery due to loss of insulin to an external leak. If insulin is not delivered properly, users may experience high blood glucose levels due to under-delivery of in... Action: Insulet initially issued a press release on 05/26/2026 along with an \"Urgent: Medical Device Correction\" on the same day. Consig...", "whyItMatters": "Device and supply recalls can affect insulin delivery, glucose readings, replacement needs, and urgent family safety decisions.", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?id=220614", "publishedAt": "2026-06-30", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "safety", "recall", "fda", "device" ], "metadata": { "cfresId": "220614", "recallNumber": "Z-2603-2026", "status": "Open, Classified", "firm": "Insulet Corporation", "initiatedAt": "2026-05-20", "postedAt": "2026-06-30" } }, { "id": "openfda-device-recall:220615", "sourceId": "openfda_device_recalls", "sourceName": "openFDA device recalls", "category": "Safety", "trustTier": "T0", "evidenceLabel": "FDA recall database", "urgency": "Act", "title": "Insulet Corporation: Omnipod DASH Pod. Includes the below Model/REF Numbers: 1. POD-BLE-I1-525 (5-Pack), POD-BLE-I1-520 (Single Pod). 2. POD-BLE-I1-529 (10-Pack), POD-BLE-I1-520 (Single Pod). 3. BLE-I...", "summary": "External soft cannula damage during manufacturing that results in insulin leaking around the Pod instead of being delivered to the user regardless of basal or bolus delivery. The primary failure mode is pump under-delivery due to loss of insulin to an external leak. If insulin is not delivered properly, users may experience high blood glucose levels due to under-delivery of in... Action: Insulet initially issued a press release on 05/26/2026 along with an \"Urgent: Medical Device Correction\" on the same day. Consig...", "whyItMatters": "Device and supply recalls can affect insulin delivery, glucose readings, replacement needs, and urgent family safety decisions.", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?id=220615", "publishedAt": "2026-06-30", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "safety", "recall", "fda", "device" ], "metadata": { "cfresId": "220615", "recallNumber": "Z-2604-2026", "status": "Open, Classified", "firm": "Insulet Corporation", "initiatedAt": "2026-05-20", "postedAt": "2026-06-30" } }, { "id": "openfda-device-recall:220616", "sourceId": "openfda_device_recalls", "sourceName": "openFDA device recalls", "category": "Safety", "trustTier": "T0", "evidenceLabel": "FDA recall database", "urgency": "Act", "title": "Insulet Corporation: Omnipod (Eros) Pod. Includes the below Model/REF Numbers: 1. POD-ZXP425 (10 Pack), POD- ZXP420 (Single Pod). 2. ZXR425 (10-Pack), ZXR420 (Single Pod). 3. ZXP425 (10 Pack), ZXP420...", "summary": "External soft cannula damage during manufacturing that results in insulin leaking around the Pod instead of being delivered to the user regardless of basal or bolus delivery. The primary failure mode is pump under-delivery due to loss of insulin to an external leak. If insulin is not delivered properly, users may experience high blood glucose levels due to under-delivery of in... Action: Insulet initially issued a press release on 05/26/2026 along with an \"Urgent: Medical Device Correction\" on the same day. Consig...", "whyItMatters": "Device and supply recalls can affect insulin delivery, glucose readings, replacement needs, and urgent family safety decisions.", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?id=220616", "publishedAt": "2026-06-30", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "safety", "recall", "fda", "device" ], "metadata": { "cfresId": "220616", "recallNumber": "Z-2605-2026", "status": "Open, Classified", "firm": "Insulet Corporation", "initiatedAt": "2026-05-20", "postedAt": "2026-06-30" } }, { "id": "clinicaltrials:NCT07212530", "sourceId": "clinicaltrials_gov_v2", "sourceName": "ClinicalTrials.gov", "category": "Trials", "trustTier": "T0", "evidenceLabel": "Official recruiting registry", "urgency": "Act", "title": "EmoTIChealth: Promoting Adolescent Health Through a Serious Game.", "summary": "RECRUITING, NA. Interventions: EmoTIChealth. Locations: Valencia, Valencia, Spain. The intervention program targets adolescents between 12 and 16 years of age. The intervention program is designed for adolescents during a critical developmental stage marked by significant life transitions, where building strong personal resources and receiving psychological support is essential to foster socioemotional skills and overall well-being. The serious game aims...", "whyItMatters": "Recruiting status can change quickly. Families should review official eligibility, location, burden, and care-team fit before sharing health information.", "url": "https://clinicaltrials.gov/study/NCT07212530", "publishedAt": "2026-05-13", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "trial", "recruiting", "clinicaltrials.gov" ], "metadata": { "nctId": "NCT07212530", "status": "RECRUITING", "phase": "NA", "interventions": "EmoTIChealth", "locations": "Valencia, Valencia, Spain" } }, { "id": "clinicaltrials:NCT02000687", "sourceId": "clinicaltrials_gov_v2", "sourceName": "ClinicalTrials.gov", "category": "Trials", "trustTier": "T0", "evidenceLabel": "Official recruiting registry", "urgency": "Act", "title": "Long Term Surveillance of Islet Transplant Recipients Following Complete Graft Loss", "summary": "RECRUITING. Locations: Miami, Florida, United States. This is a single-center, prospective, open label study in islet transplant recipients following islet graft loss.", "whyItMatters": "Recruiting status can change quickly. Families should review official eligibility, location, burden, and care-team fit before sharing health information.", "url": "https://clinicaltrials.gov/study/NCT02000687", "publishedAt": "2026-03-23", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "trial", "recruiting", "clinicaltrials.gov" ], "metadata": { "nctId": "NCT02000687", "status": "RECRUITING", "phase": "", "interventions": "", "locations": "Miami, Florida, United States" } }, { "id": "clinicaltrials:NCT01630850", "sourceId": "clinicaltrials_gov_v2", "sourceName": "ClinicalTrials.gov", "category": "Trials", "trustTier": "T0", "evidenceLabel": "Official recruiting registry", "urgency": "Act", "title": "Islet Transplantation in Patients With \"Brittle\" Type I Diabetes", "summary": "RECRUITING, NA. Interventions: Allogenic islet cells (human, U. Chicago), Intraportal infusion of islet cells. Locations: Chicago, Illinois, United States. The purpose of this study is to learn about the safety of islet transplantation for Type 1 diabetes mellitus, which may provide more normal control of blood sugar without the need for insulin shots. Islets are special clusters of cells within the pancreas that produce insulin. These cells will be obtai...", "whyItMatters": "Recruiting status can change quickly. Families should review official eligibility, location, burden, and care-team fit before sharing health information.", "url": "https://clinicaltrials.gov/study/NCT01630850", "publishedAt": "2025-12-09", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "trial", "recruiting", "clinicaltrials.gov" ], "metadata": { "nctId": "NCT01630850", "status": "RECRUITING", "phase": "NA", "interventions": "Allogenic islet cells (human, U. Chicago), Intraportal infusion of islet cells", "locations": "Chicago, Illinois, United States" } }, { "id": "clinicaltrials:NCT07193446", "sourceId": "clinicaltrials_gov_v2", "sourceName": "ClinicalTrials.gov", "category": "Trials", "trustTier": "T0", "evidenceLabel": "Official recruiting registry", "urgency": "Act", "title": "Optimising the Delivery of Diabetes Distress Informed Care for Its Prevention, Detection, and Management in Adults With Type 1 Diabetes: a Feasibility Study (D-stress Study)", "summary": "RECRUITING, NA. Interventions: D-stress study: The detection, prevention and management of diabetes distress for adults living with type 1 diabetes.. Locations: Bath, United Kingdom | Leicester, United Kingdom | London, United Kingdom. Up to one in two adults with type 1 diabetes find living with and managing diabetes to be emotionally challenging. This 'emotional side' of diabetes - feeling worried, frustrated, overwhelmed, sad, burnt-out - is called dia...", "whyItMatters": "Recruiting status can change quickly. Families should review official eligibility, location, burden, and care-team fit before sharing health information.", "url": "https://clinicaltrials.gov/study/NCT07193446", "publishedAt": "2025-12-04", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "trial", "recruiting", "clinicaltrials.gov" ], "metadata": { "nctId": "NCT07193446", "status": "RECRUITING", "phase": "NA", "interventions": "D-stress study: The detection, prevention and management of diabetes distress for adults living with type 1 diabetes.", "locations": "Bath, United Kingdom | Leicester, United Kingdom | London, United Kingdom" } }, { "id": "clinicaltrials:NCT07144696", "sourceId": "clinicaltrials_gov_v2", "sourceName": "ClinicalTrials.gov", "category": "Trials", "trustTier": "T0", "evidenceLabel": "Official recruiting registry", "urgency": "Act", "title": "Study on the Improvement of Metabolic Indicators in Type 1 Diabetes Patients", "summary": "RECRUITING, NA. Interventions: structured education and regular follow-up. Locations: Beijing, China. In this study, type 1 diabetes patients from the outpatient department of Peking University First Hospital were selected as the research objects. The investigators plan to recruit 150 participants. Using the course and teaching plan of \\"Take Control of My Life - Structured Education for Type 1 diabetes\\" issued by the China Type 1 diabetes Allian...", "whyItMatters": "Recruiting status can change quickly. Families should review official eligibility, location, burden, and care-team fit before sharing health information.", "url": "https://clinicaltrials.gov/study/NCT07144696", "publishedAt": "2025-09-04", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "trial", "recruiting", "clinicaltrials.gov" ], "metadata": { "nctId": "NCT07144696", "status": "RECRUITING", "phase": "NA", "interventions": "structured education and regular follow-up", "locations": "Beijing, China" } }, { "id": "clinicaltrials:NCT06951074", "sourceId": "clinicaltrials_gov_v2", "sourceName": "ClinicalTrials.gov", "category": "Trials", "trustTier": "T0", "evidenceLabel": "Official recruiting registry", "urgency": "Act", "title": "Insulin Producing Stem Cell Transplantation Clinical Trial in Type 1 Diabetes", "summary": "RECRUITING, PHASE2, PHASE3. Interventions: Insulin producing stem cells infusion. Locations: Cairo, Egypt. Type 1 Diabetes is a chronic autoimmune disease. It results from autoimmune destruction of pancreatic Beta cells leading to absolute insulin insufficiency. The establishment of pluripotent like human stem cells derived from adipose tissue derived mesenchymal cell origin have introduced a new potential source for cell therapy in type 1 diabetic patien...", "whyItMatters": "Recruiting status can change quickly. Families should review official eligibility, location, burden, and care-team fit before sharing health information.", "url": "https://clinicaltrials.gov/study/NCT06951074", "publishedAt": "2025-04-30", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "trial", "recruiting", "clinicaltrials.gov" ], "metadata": { "nctId": "NCT06951074", "status": "RECRUITING", "phase": "PHASE2, PHASE3", "interventions": "Insulin producing stem cells infusion", "locations": "Cairo, Egypt" } }, { "id": "clinicaltrials:NCT03316261", "sourceId": "clinicaltrials_gov_v2", "sourceName": "ClinicalTrials.gov", "category": "Trials", "trustTier": "T0", "evidenceLabel": "Official recruiting registry", "urgency": "Act", "title": "Freder1k-Study - Testing Infants for Type 1 Diabetes Risk", "summary": "RECRUITING. Locations: Munich, Germany. The Freder1k-Study will identify infants who have a high genetic risk of type 1 diabetes.", "whyItMatters": "Recruiting status can change quickly. Families should review official eligibility, location, burden, and care-team fit before sharing health information.", "url": "https://clinicaltrials.gov/study/NCT03316261", "publishedAt": "2024-12-17", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "trial", "recruiting", "clinicaltrials.gov" ], "metadata": { "nctId": "NCT03316261", "status": "RECRUITING", "phase": "", "interventions": "", "locations": "Munich, Germany" } }, { "id": "clinicaltrials:NCT04629586", "sourceId": "clinicaltrials_gov_v2", "sourceName": "ClinicalTrials.gov", "category": "Trials", "trustTier": "T0", "evidenceLabel": "Official recruiting registry", "urgency": "Act", "title": "The T1D Exchange Registry", "summary": "RECRUITING. Interventions: No intervention. Locations: Boston, Massachusetts, United States. The T1D Exchange Registry is a research study, conducted over time, for individuals with type 1 diabetes and their supporters. Participants volunteer to provide their data for research (for example, by answering questions in annual surveys). Once enrolled, Registry participants have the opportunity to sign up for other studies on various topics related to type 1 d...", "whyItMatters": "Recruiting status can change quickly. Families should review official eligibility, location, burden, and care-team fit before sharing health information.", "url": "https://clinicaltrials.gov/study/NCT04629586", "publishedAt": "2023-05-08", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "trial", "recruiting", "clinicaltrials.gov" ], "metadata": { "nctId": "NCT04629586", "status": "RECRUITING", "phase": "", "interventions": "No intervention", "locations": "Boston, Massachusetts, United States" } }, { "id": "pubmed:42790360", "sourceId": "pubmed_ncbi_eutilities", "sourceName": "PubMed", "category": "Research", "trustTier": "T1", "evidenceLabel": "PubMed indexed literature", "urgency": "Track", "title": "Engineering a bijel-templated material-integrated cannula for subcutaneous insulin delivery: Design, fabrication, in vivo delivery characterization, and failure analysis.", "summary": "Biomaterials advances. Authors: Groisman L, Thorson TJ, Saudi B. Journal Article", "whyItMatters": "This belongs in the research watch lane for clinical relevance review, evidence labeling, and parent-readable interpretation before any action is implied.", "url": "https://pubmed.ncbi.nlm.nih.gov/42790360/", "publishedAt": "2026-10-20", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "research", "pubmed", "type 1 diabetes" ], "metadata": { "pmid": "42790360", "journal": "Biomaterials advances", "publicationTypes": [ "Journal Article" ] } }, { "id": "pubmed:42598441", "sourceId": "pubmed_ncbi_eutilities", "sourceName": "PubMed", "category": "Research", "trustTier": "T1", "evidenceLabel": "PubMed indexed literature", "urgency": "Track", "title": "Retrievable \"sea-island\" microstructured zwitterionic-silicone hydrogel devices: augmented oxygen transport and anti-fibrosis for sustaining islet survival.", "summary": "Bioactive materials. Authors: Chen D, Wang H, Tang Y. Journal Article", "whyItMatters": "This belongs in the research watch lane for clinical relevance review, evidence labeling, and parent-readable interpretation before any action is implied.", "url": "https://pubmed.ncbi.nlm.nih.gov/42598441/", "publishedAt": "2026-10-20", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "research", "pubmed", "type 1 diabetes" ], "metadata": { "pmid": "42598441", "journal": "Bioactive materials", "publicationTypes": [ "Journal Article" ] } }, { "id": "pubmed:42430551", "sourceId": "pubmed_ncbi_eutilities", "sourceName": "PubMed", "category": "Research", "trustTier": "T1", "evidenceLabel": "PubMed indexed literature", "urgency": "Track", "title": "IFNα and bleomycin-induced DNA damage activate distinct stress responses in human islets and induced pluripotent stem cell-derived islet cells.", "summary": "Islets. Authors: Akbari Motlagh R, Rampazzo Morelli N, Alcasid N. Journal Article", "whyItMatters": "This belongs in the research watch lane for clinical relevance review, evidence labeling, and parent-readable interpretation before any action is implied.", "url": "https://pubmed.ncbi.nlm.nih.gov/42430551/", "publishedAt": "2026-10-20", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "research", "pubmed", "type 1 diabetes" ], "metadata": { "pmid": "42430551", "journal": "Islets", "publicationTypes": [ "Journal Article" ] } }, { "id": "pubmed:42070103", "sourceId": "pubmed_ncbi_eutilities", "sourceName": "PubMed", "category": "Research", "trustTier": "T1", "evidenceLabel": "PubMed indexed literature", "urgency": "Track", "title": "Human and mouse regenerative macrophages enhance beta cell survival, function, and proliferation.", "summary": "Islets. Authors: Monajemi M, Craciun AS, Huang Q. Journal Article", "whyItMatters": "This belongs in the research watch lane for clinical relevance review, evidence labeling, and parent-readable interpretation before any action is implied.", "url": "https://pubmed.ncbi.nlm.nih.gov/42070103/", "publishedAt": "2026-10-20", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "research", "pubmed", "type 1 diabetes" ], "metadata": { "pmid": "42070103", "journal": "Islets", "publicationTypes": [ "Journal Article" ] } }, { "id": "pubmed:42017902", "sourceId": "pubmed_ncbi_eutilities", "sourceName": "PubMed", "category": "Research", "trustTier": "T1", "evidenceLabel": "PubMed indexed literature", "urgency": "Track", "title": "Is the intraportal or renal subcapsular space a preferable site for islet allo- and xeno-transplantation? A brief historical review.", "summary": "Islets. Authors: De Taeye S, Bottino R, Cooper DKC. Journal Article, Review", "whyItMatters": "This belongs in the research watch lane for clinical relevance review, evidence labeling, and parent-readable interpretation before any action is implied.", "url": "https://pubmed.ncbi.nlm.nih.gov/42017902/", "publishedAt": "2026-10-20", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "research", "pubmed", "type 1 diabetes" ], "metadata": { "pmid": "42017902", "journal": "Islets", "publicationTypes": [ "Journal Article", "Review" ] } }, { "id": "pubmed:41774510", "sourceId": "pubmed_ncbi_eutilities", "sourceName": "PubMed", "category": "Research", "trustTier": "T1", "evidenceLabel": "PubMed indexed literature", "urgency": "Track", "title": "MLPH/RAB3A accelerates the differentiation of pancreatic stem cells to islet β-cells to control blood glucose in diabetic rats.", "summary": "Organogenesis. Authors: Shan J, Wang H, Zhu G. Journal Article", "whyItMatters": "This belongs in the research watch lane for clinical relevance review, evidence labeling, and parent-readable interpretation before any action is implied.", "url": "https://pubmed.ncbi.nlm.nih.gov/41774510/", "publishedAt": "2026-10-20", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "research", "pubmed", "type 1 diabetes" ], "metadata": { "pmid": "41774510", "journal": "Organogenesis", "publicationTypes": [ "Journal Article" ] } }, { "id": "pubmed:42878112", "sourceId": "pubmed_ncbi_eutilities", "sourceName": "PubMed", "category": "Research", "trustTier": "T1", "evidenceLabel": "PubMed indexed literature", "urgency": "Track", "title": "Treatment patterns, healthcare utilization, and healthcare costs in patients with newly diagnosed type 1 diabetes: a retrospective real-world study in Tianjin, China.", "summary": "Journal of medical economics. Authors: Liu W, Ji L, Chen Y. Journal Article", "whyItMatters": "This belongs in the research watch lane for clinical relevance review, evidence labeling, and parent-readable interpretation before any action is implied.", "url": "https://pubmed.ncbi.nlm.nih.gov/42878112/", "publishedAt": "2026-10-20", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "research", "pubmed", "type 1 diabetes" ], "metadata": { "pmid": "42878112", "journal": "Journal of medical economics", "publicationTypes": [ "Journal Article" ] } }, { "id": "pubmed:42733922", "sourceId": "pubmed_ncbi_eutilities", "sourceName": "PubMed", "category": "Research", "trustTier": "T1", "evidenceLabel": "PubMed indexed literature", "urgency": "Track", "title": "Deletion of the T1D risk gene Ormdl3 in β-cells does not impact disease progression.", "summary": "Biochemistry and biophysics reports. Authors: Ou Q, Jones EF, Currey K. Journal Article", "whyItMatters": "This belongs in the research watch lane for clinical relevance review, evidence labeling, and parent-readable interpretation before any action is implied.", "url": "https://pubmed.ncbi.nlm.nih.gov/42733922/", "publishedAt": "2026-10-20", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "research", "pubmed", "type 1 diabetes" ], "metadata": { "pmid": "42733922", "journal": "Biochemistry and biophysics reports", "publicationTypes": [ "Journal Article" ] } }, { "id": "pubmed:42539632", "sourceId": "pubmed_ncbi_eutilities", "sourceName": "PubMed", "category": "Research", "trustTier": "T1", "evidenceLabel": "PubMed indexed literature", "urgency": "Track", "title": "Glutamate-glutamine axis in pancreatic β-cells: mechanistic insights and therapeutic prospects in diabetes and its complications.", "summary": "Journal of diabetes and metabolic disorders. Authors: Olatunde A, Disina HB, Eyitayo AR. Journal Article, Review", "whyItMatters": "This belongs in the research watch lane for clinical relevance review, evidence labeling, and parent-readable interpretation before any action is implied.", "url": "https://pubmed.ncbi.nlm.nih.gov/42539632/", "publishedAt": "2026-10-20", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "research", "pubmed", "type 1 diabetes" ], "metadata": { "pmid": "42539632", "journal": "Journal of diabetes and metabolic disorders", "publicationTypes": [ "Journal Article", "Review" ] } }, { "id": "pubmed:42524453", "sourceId": "pubmed_ncbi_eutilities", "sourceName": "PubMed", "category": "Research", "trustTier": "T1", "evidenceLabel": "PubMed indexed literature", "urgency": "Track", "title": "Perceptions of adults with type 1 diabetes mellitus about diabetes management and exercise.", "summary": "Human factors in healthcare. Authors: Swaminath M, Griggs SA, Lukasik J. Journal Article", "whyItMatters": "This belongs in the research watch lane for clinical relevance review, evidence labeling, and parent-readable interpretation before any action is implied.", "url": "https://pubmed.ncbi.nlm.nih.gov/42524453/", "publishedAt": "2026-10-20", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "research", "pubmed", "type 1 diabetes" ], "metadata": { "pmid": "42524453", "journal": "Human factors in healthcare", "publicationTypes": [ "Journal Article" ] } }, { "id": "pubmed:42395262", "sourceId": "pubmed_ncbi_eutilities", "sourceName": "PubMed", "category": "Research", "trustTier": "T1", "evidenceLabel": "PubMed indexed literature", "urgency": "Track", "title": "AutoBiGluNet: transformer-based time series modeling for blood glucose prediction in Type 1 diabetes patients.", "summary": "Health information science and systems. Authors: Sarwar MA, Maqsood S, Belousoviene E. Journal Article", "whyItMatters": "This belongs in the research watch lane for clinical relevance review, evidence labeling, and parent-readable interpretation before any action is implied.", "url": "https://pubmed.ncbi.nlm.nih.gov/42395262/", "publishedAt": "2026-10-20", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "research", "pubmed", "type 1 diabetes" ], "metadata": { "pmid": "42395262", "journal": "Health information science and systems", "publicationTypes": [ "Journal Article" ] } }, { "id": "pubmed:41823267", "sourceId": "pubmed_ncbi_eutilities", "sourceName": "PubMed", "category": "Research", "trustTier": "T1", "evidenceLabel": "PubMed indexed literature", "urgency": "Track", "title": "Role of small intronic RNAs in the crosstalk between immune cells and β-cells during type 1 diabetes development.", "summary": "RNA biology. Authors: Poddar S, Brozzi F, Cosentino C. Journal Article", "whyItMatters": "This belongs in the research watch lane for clinical relevance review, evidence labeling, and parent-readable interpretation before any action is implied.", "url": "https://pubmed.ncbi.nlm.nih.gov/41823267/", "publishedAt": "2026-10-20", "fetchedAt": "2026-10-20T01:17:02.002Z", "tags": [ "research", "pubmed", "type 1 diabetes" ], "metadata": { "pmid": "41823267", "journal": "RNA biology", "publicationTypes": [ "Journal Article" ] } } ] }